Avotaciclib trihydrochloride

• CAT Number: I022737
• CAS Number: 1983984-01-5
• Molecular Formula: C13H14Cl3N7O
• Molecular Weight: 390.66
• Purity: ≥95%
• Synonyms: 2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol;trihydrochloride
• InChI: InChI=1S/C13H11N7O.3ClH/c14-12-16-5-3-8(19-12)7-1-2-10(21)11(18-7)9-4-6-17-13(15)20-9;;;/h1-6,21H,(H2,14,16,19)(H2,15,17,20);3*1H
• InChIKey: YUNYDIDVURXULR-UHFFFAOYSA-N
• SMILES: C1=CC(=NC(=C1O)C2=NC(=NC=C2)N)C3=NC(=NC=C3)N.Cl.Cl.Cl

Avotaciclib trihydrochloride (Cat No.:I022737) is an oral, selective inhibitor of cyclin-dependent kinase 9 (CDK9), a key regulator of transcriptional elongation and anti-apoptotic gene expression such as MCL-1. By blocking CDK9 activity, avotaciclib disrupts the transcription of survival proteins in cancer cells, leading to apoptosis, particularly in hematologic malignancies and transcriptionally addicted tumors. It has shown promising preclinical activity and is currently under clinical investigation. Avotaciclib trihydrochloride represents a targeted approach to suppress oncogenic transcription and overcome resistance mechanisms in cancer therapy.